Report more than two alcoholic beverages daily or more than 14 alcoholic beverages weekly withing 7 days of study start.

Have a known history of neuroleptic malignant syndrome.

Have a positive human immunodeficiency virus (HIV) antibody result at screening or have a history of positive result.

Have received an investigational drug within 30 days before screening or plan to use an investigational drug (other than NBI-98854) during the study.

Have an allergy, hypersensitivity, or intolerance to tetrabenazine.

Had a blood loss greater than or equal to 500 mL or donated blood within 56 days of study start.

Have had previous exposure with NBI-98854.

Safety, Tolerability, and Pharmacokinetics of a Single Dose of NBI-98854 in Subjects With Mild,Moderate, or Severe Hepatic Insufficiency